Literature DB >> 16822566

The clinical study of autologous peripheral blood stem cell transplantation by intracoronary infusion in patients with acute myocardial infarction (AMI).

Zhan-quan Li1, Ming Zhang, Yuan-zhe Jing, Wei-wei Zhang, Ying Liu, Li-jie Cui, Long Yuan, Xian-zhi Liu, Xian Yu, Tie-shi Hu.   

Abstract

PURPOSE: To investigate the effects and safety of autologous peripheral blood stem cell (PBSCs) transplantation by intracoronary infusion in patients with acute myocardial infarction (AMI).
METHODS: 70 patients with AMI were allocated to two groups, one was PBSCs transplantation group (n=35) that received optimal post-infarction medical treatment (standard drug and coronary artery intervention therapy) and intracoronary transplantation of PBSCs; the other was control group (n=35) that received optimum post-infarction medical treatment (standard drug and coronary artery intervention therapy). The PBSCs transplantation group received granulocyte colony-stimulating factor (G-CSF: Filgrastim, 300 microg) with the dose of 300-600 microg/day to mobilize the stem cell, and the duration of administration G-CSF was 5 days. On the sixth day, PBSCs were separated by Baxter CS 3000 blood cell separator into suspend liquid 57 ml. Then, the suspend liquid was transferred into the infarct-related artery (IRA) by occluding the over-the-wire balloon and infusing artery through balloon center lumen. In the process of the mobilization, separation and intracoronary infusion of PBSCs, the complications have been investigated. Changes in left ventricular function were assessed at 6-month follow-up.
RESULTS: 35 cases had finished follow-up in the treated group, while 23 cases in control group. After 6 months, within the treated group, there was a significant improvement in global left ventricular function ejection fraction (EF) from a baseline of 50.0+/-8.2% to 57.1+/-7.8% (P<0.0001), wall motion score index (WMSI) from 1.219+/-0.190 to 1.101+/-0.118 (P<0.0001), left end-systolic volume (ESV) from 63.8+/-23.9 ml to 52.6+/-20.3 ml (P=0.01) and left end-diastolic volume (EDV) from 134.2+/-36.7 ml to 119.2+/-30.3 ml (P=0.07); in the control group, there was no significant improvement in EF, WISM, EDV and ESV (P=0.490, 0.259, 0.117, 0.395). After 6-month follow-up, according to treatment group vs. control group, there was a significant improvement in EF from 57.1+/-7.8 to 52.6+/-5.7 (P=0.041) and WISM from 1.101+/-0.118 to 1.184+/-0.138 (P=0.034). There were a total of 25 cases with complications during the mobilization, separating and infusion of PBSC. The incidence of complications relating to mobilization was 37.1% (13/35), relating to separating was 14.3% (5/35) and relating to intracoronary infusion was 20.0% (7/35). No death was observed.
CONCLUSION: Autologous PBSCs transplantation by intracoronary infusion is feasible and safe, and it can improve left ventricular function in the 6-month follow-up.

Entities:  

Mesh:

Year:  2006        PMID: 16822566     DOI: 10.1016/j.ijcard.2006.04.005

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  33 in total

Review 1.  Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells.

Authors:  Sangho Lee; Young-Sup Yoon
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 2.  Cell delivery routes for stem cell therapy to the heart: current and future approaches.

Authors:  Niall G Campbell; Ken Suzuki
Journal:  J Cardiovasc Transl Res       Date:  2012-05-31       Impact factor: 4.132

3.  The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion.

Authors:  Kamel Sadat; Sameer Ather; Wael Aljaroudi; Jaekyeong Heo; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2013-12-31       Impact factor: 5.952

4.  Cell therapy for myocardial infarction.

Authors:  Yoo-Wook Kwon; Han-Mo Yang; Hyun-Jai Cho
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

5.  Impact of balloon inflation pressure on cell viability with single and multi lumen catheters.

Authors:  N Dib; D B Schwalbach; B D Plourde; R E Kohler; D Dana; J P Abraham
Journal:  J Cardiovasc Transl Res       Date:  2014-11-21       Impact factor: 4.132

Review 6.  Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all!

Authors:  C V Borlongan
Journal:  Leukemia       Date:  2011-07-05       Impact factor: 11.528

7.  Clinical trials of cardiac repair with adult bone marrow- derived cells.

Authors:  Vinodh Jeevanantham; Mohammad R Afzal; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Methods Mol Biol       Date:  2013

8.  Cord blood-circulating endothelial progenitors for treatment of vascular diseases.

Authors:  M Lavergne; V Vanneaux; C Delmau; E Gluckman; I Rodde-Astier; J Larghero; G Uzan
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

Review 9.  Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.

Authors:  Paulino A Alvarez; Ernst R Schwarz; Rajesh Ramineni; Phil Myatt; Clay Barbin; Carlos Boissonnet; Anita Phan; Aldo Maggioni; Alejandro Barbagelata
Journal:  Clin Res Cardiol       Date:  2012-09-28       Impact factor: 5.460

Review 10.  Cardiac repair with adult bone marrow-derived cells: the clinical evidence.

Authors:  Buddhadeb Dawn; Ahmed Abdel-Latif; Santosh K Sanganalmath; Michael P Flaherty; Ewa K Zuba-Surma
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.